nidogen-2、HE4和TK1在卵巢癌中的表达意义研究

Value of expressions of serum nidogen-2,HE4 and TK1 in diagnosis of ovarian cancer

目的分析nidogen-2、HE4和TK1联合检测在卵巢癌中的诊断价值。方法将2015年10月至2017年10月因卵巢癌于金华市人民医院治疗的74例患者(卵巢癌组),以及同期收治的48例良性卵巢疾病患者(良性组)、45例健康女性(对照组)作为研究对象。分析三组研究对象机体内nidogen-2、HE4和TK1等指标表达情况,分析上述三种肿瘤标志物在卵巢癌中的诊断价值。结果卵巢癌组nidogen-2、HE4和TK1等指标表达量显著高于良性组、对照组(t值分别为21.36、26.97、15.22、23.69、29.55、16.01,均P<0.05),但良性组与对照组上述指标比较无显著性差异(t值分别为1.41、1.85、1.22、1.08,均P>0.05)。卵巢癌组nidogen-2、HE4和TK1阳性表达率均高于良性组与对照组(χ2值分别为8.991、7.695,均P<0.05)。对于卵巢癌患者,不同检测方法敏感性、特异性、准确率均有显著性差异(χ2值分别为29.321、98.129、31.941,均P<0.05),三联检测均最高。结论 nidogen-2、HE4和TK1联合检测可有效提高卵巢癌诊断的敏感性、特异性及诊断准确率,可考虑临床推广应用。

Objective To analyze the value of combined detecting serum nidogen-2,HE4 and TK1 in diagnosis of ovarian cancer.Methods Research subjects included 74 patients with ovarian cancer（ovarian cancer group）and 48 patients with benign ovarian disease（benign group）treated in Jinhua People＇s Hospital from October 2015 to October 2017 and 45 healthy women（control group）.The expressions of nidogen-2,HE4 and TK1 of patients in three groups were analyzed for their diagnostic value on ovarian cancer.Results The expressions of nidogen-2,HE4 and TK1 in ovarian cancer group were significantly higher than those in benign group and control group（t value was 21.36,26.97,15.22,23.69,29.55 and 16.01,respectively,all P〈0.05）,but there were no significant differences between benign group and control group（t value was 1.41,1.85,1.22 and 1.08,respectively,all P〉0.05）.The positive rates of nidogen-2,HE4 and TK1 in ovarian cancer group were significantly higher than those in benign group and control group（χ^2 value was 8.991 and 7.695,respectively,both P〈0.05）.For patients with ovarian cancer,detecting methods were remarkably different in sensitivity,specificity and accuracy（χ^2 value was 29.321,98.129 and 31.941,respectively,all P〈0.05）.Combined detecting of three indexes obtained highest sensitivity,specificity and accuracy.Conclusion The combination of detecting nidogen-2,HE4 and TK1 can effectively improve the sensitivity,specificity and accuracy of clinical diagnosis of ovarian cancer,which might be considered for clinical application.